share_log

贝达药业(300558.SZ)：已拥有凯美纳、贝美纳、赛美纳、伏美纳、贝安汀五款上市产品

Betta Pharmaceuticals (300558.SZ): It already has five marketed products: Kaimena, Bemena, Saimena, Vomena, and Beantin

Gelonghui Finance ·  Apr 9 04:38

Gelonghui, April 9 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that the company already has five listed products: Kaimena, Bemena, Saimena, Vomena, and Beantin. Each product has its own launch point and life cycle. The company formulates targeted promotion strategies for each product and promotes implementation. Since the launch of Kaimena, indication expansion has continued to extend the product life cycle; Bemena was listed in November 2020, with clinically differentiated data advantages, and continued to contribute to the company's revenue growth; Beantin was listed in November 2021. Through professional promotion and accelerated market entry, sales growth met expectations; Saimena and Vumena were approved in May and June 2023 respectively, and sales were achieved quickly after launch. Currently, the company's revenue sources are diversified, and in the future, it will continue to make use of its successful experience in product commercialization and strive to increase the scale of revenue.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment